Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alternative RNA Splicing02:18

Alternative RNA Splicing

25.2K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
25.2K
Alternative RNA Splicing02:18

Alternative RNA Splicing

5.2K
5.2K
RNA Splicing01:32

RNA Splicing

60.7K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
60.7K
Null and Alternative Hypotheses01:16

Null and Alternative Hypotheses

12.8K
The actual hypothesis testing begins by considering two hypotheses. They are termed  the null hypothesis and the alternative hypothesis. These hypotheses contain opposing viewpoints.
The null hypothesis, denoted by H0 is a statement of no difference between the variables—they are not related. This can often be considered the status quo. As  a result if you cannot accept the null, it requires some action.
The alternative hypothesis, denoted by H1 or Ha, is a claim about the...
12.8K
Chromatin Structure and RNA Splicing02:41

Chromatin Structure and RNA Splicing

3.5K
3.5K
Pre-mRNA Processing: RNA Splicing01:36

Pre-mRNA Processing: RNA Splicing

6.9K
6.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer.

Investigational new drugs·2026
Same author

Decoding the Raf-Mek-Erk-Rsk pathway in prostate cancer: from molecular mechanisms to clinical opportunities.

British journal of cancer·2026
Same author

Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Splicing factor TRA2B enhances synthesis of androgen receptor variant AR-V7 in prostate cancer cells.

The Journal of clinical investigation·2026
Same author

Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers.

The Journal of clinical investigation·2026
Same journal

Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.

Nature reviews. Clinical oncology·2026
Same journal

Patient value over patent value: the mandate for open-source oncology.

Nature reviews. Clinical oncology·2026
Same journal

Cancer burden and control in China: landscape, trends and challenges.

Nature reviews. Clinical oncology·2026
Same journal

Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.

Nature reviews. Clinical oncology·2026
Same journal

New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer.

Nature reviews. Clinical oncology·2026
Same journal

Teclistamab monotherapy improves survival in RRMM.

Nature reviews. Clinical oncology·2026
See all related articles

Related Experiment Video

Updated: Feb 6, 2026

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
11:48

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

Published on: October 9, 2014

13.4K

Alternative splicing in prostate cancer.

Alec Paschalis1,2, Adam Sharp1,2, Jonathan C Welti1

  • 1The Institute for Cancer Research, London, UK.

Nature Reviews. Clinical Oncology
|August 24, 2018
PubMed
Summary
This summary is machine-generated.

Androgen receptor splice variants (AR-Vs) drive lethal prostate cancer and therapy resistance. Targeting the spliceosome offers a novel therapeutic strategy to disrupt AR-V formation and improve patient outcomes.

More Related Videos

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

9.4K
Identification of Alternative Splicing and Polyadenylation in RNA-seq Data
08:35

Identification of Alternative Splicing and Polyadenylation in RNA-seq Data

Published on: June 24, 2021

6.5K

Related Experiment Videos

Last Updated: Feb 6, 2026

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
11:48

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

Published on: October 9, 2014

13.4K
Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

9.4K
Identification of Alternative Splicing and Polyadenylation in RNA-seq Data
08:35

Identification of Alternative Splicing and Polyadenylation in RNA-seq Data

Published on: June 24, 2021

6.5K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Androgen receptor (AR) splice variants (AR-Vs) are key drivers in metastatic prostate cancer progression.
  • AR-Vs, such as AR-V7, promote cancer cell proliferation and confer resistance to anti-androgen therapies and radiotherapy.
  • Current therapeutic strategies to inhibit AR-Vs have been unsuccessful, necessitating novel approaches.

Purpose of the Study:

  • To review the current understanding of the spliceosome's role in prostate cancer progression.
  • To explore the therapeutic potential of modulating alternative splicing to target AR-Vs.
  • To highlight the need for spliceosome-targeted agents in prostate cancer treatment.

Main Methods:

  • Literature review of existing research on AR-Vs, spliceosomes, and prostate cancer.
  • Analysis of the biological mechanisms underlying AR-V formation and spliceosome function.
  • Synthesis of current knowledge to identify therapeutic avenues.

Main Results:

  • AR-Vs contribute to treatment resistance and unfavorable clinical outcomes in prostate cancer patients.
  • The spliceosome plays a critical role in alternative splicing events that generate oncogenic AR-Vs.
  • Modulating spliceosome activity presents a promising strategy for disrupting AR-V formation.

Conclusions:

  • The spliceosome is a critical regulator of AR-V production in prostate cancer.
  • Targeting the spliceosome offers a novel therapeutic avenue for overcoming AR-V-mediated resistance.
  • Further research into spliceosome biology is crucial for developing effective spliceosome-targeted therapies for prostate cancer.